Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD [clinicaltrials:NCT00157339]

Bio2RDF identifier

NCT00157339

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00157339

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00157339

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

299

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00157339 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00157339/arm-group/c4ca4238a0b923820dcc509a6f75849b]

NCT00157339 arm group c81e728d9d4c2f636f067f89cc14862c [clinicaltrials_resource:NCT00157339/arm-group/c81e728d9d4c2f636f067f89cc14862c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Phase 3 , open-label, r ...... month follow up period.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:4e02fa9b33189cc608a9c0ba4c3b9358]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:086f5dc3f91ea6b33b2683efa3c7edc6]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:3974025b03a3d70dd1518ba2cafef3b0]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:544f5cae963f8994a3154ccd940f05f7]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:58cb7c546a6d57850fa945e3b8fd0efa]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:6b0cc9043b4b2d53420f126f48985523]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:6cec74128ed34958f9fad89cc68924f2]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:84d7cc486e9d67dadbd16beba9ea352b]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:96203cfb7f5226c377c5dd0f94a14218]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:9ab6d6e9476cffd1fdff1d2959ac9beb]

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. 12 months [clinicaltrials_resource:d1d3436689457d2c3e52b38e9c44b85c]

collaborator [clinicaltrials_vocabulary:collaborator]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

completion date [clinicaltrials_vocabulary:completion-date]

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00157339 [clinicaltrials_resource:a6c84c48f4c4670cfbed977cd337f253]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Human Insulin Inhalation Powder [clinicaltrials_resource:90dea1b7dedbeabca456315c2f8ec8ad]

injected insulin [clinicaltrials_resource:b6411a69ecb77505c052313a77e1a07b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Insulin [clinicaltrials_resource:38ef854e1e2fa47e4184cccf82611e61]

Insulin, Globin Zinc [clinicaltrials_resource:cfe6e68d4b07bb03d3e7b7e9860f0023]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

link [clinicaltrials_vocabulary:link]

Lilly Clinical Trial Registry [clinicaltrials_resource:83adce4c7f71cdc37c40acbca0949b69]

location [clinicaltrials_vocabulary:location]

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. [clinicaltrials_resource:c9e6d7da63d1f742af07220143bf42e0]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00157339

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Pivotal, Open-Label, Paralle ...... th Diabetes and COPD or Asthma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

7.091

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hour, EST) [clinicaltrials_resource:05bad80a2efe0944a8e02e84fad6b62a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

Chief Medical Officer, Eli Lilly [clinicaltrials_resource:e579eaccf1c6bffa5de03476e056317b]

secondary id [clinicaltrials_vocabulary:secondary-id]

H7U-MC-IDAS

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]

start date [clinicaltrials_vocabulary:start-date]

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00157339 study design [clinicaltrials_resource:1ae26c23bd0395896b46210694c3ee42]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00157339

verification date [clinicaltrials_vocabulary:verification-date]

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00157339

http://www.w3.org/2001/XMLSchema#string

title

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]